The document “Notification of Issue, Conversion of Payment up of Unquoted Equity Securities” was lodged with ASX on 14 June 2021.
Please click to review the full announcement at ASX.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)